Anya Biopharm

Anya Biopharm EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Anya Biopharm (7776.TWO) as of Nov 4, 2026 is -42.39 M TWD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -28.35 M TWD — a change of 49.53% (lower).

EBITDA

-42.39 MTWD

YoY

49.53%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Anya Biopharm is 2024 -42.39 M TWD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Anya Biopharm was 2023 -28.35 M TWD. It decreases by 49.53% lower compared to the previous year.

The Anya Biopharm EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2022
-38.77 M TWD
Jan 1, 2023
-28.35 M TWD
Jan 1, 2024
-42.39 M TWD
The Anya Biopharm EBITDA history
YEAREBITDAYoY
-42.39 MTWD+49.53%
-28.35 MTWD-26.89%
-38.77 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Anya Biopharm Stock analysis

What does Anya Biopharm do? Anya Biopharm Inc generates revenue by researching and developing oral peptide dosage form platforms and new drug products within the pharmaceuticals industry. The company leverages its MIRA/JE oral peptide formulation platform to create lead products, most notably ANY002, which is a glucagon-like peptide-1 (GLP-1) receptor agonist designed for the treatment of type 2 diabetes and obesity. This core asset has advanced through early clinical pharmacokinetic trials in both animals and humans, establishing the company's value proposition in the biotech sector. The firm also markets its proprietary oral dosage form technology through the development of ANY004, which is currently in preclinical development. By focusing on these specific drug projects and formulation platforms, Anya Biopharm Inc targets the professional biotech and pharmaceutical business segments. The company operates from its headquarters in Taipei City, Taipei, and serves the global market for innovative diabetes and obesity treatments through its specialized research and development capabilities. Anya Biopharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Anya Biopharm stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Anya Biopharm is -42.39 M TWD in 2024.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Anya Biopharm changed from -28.35 M TWD to -42.39 M TWD, representing a 49.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Anya Biopharm since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Anya Biopharm historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Anya Biopharm

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Anya Biopharm